title: Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.
authors.affiliation: Indiana University School of Medicine, Indianapolis, Indiana.
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Gilbert
authors.affiliation: Georgia Regents University Medical College of Georgia, Augusta, Georgia.
authors.forename: Iviensan F
authors.initials: IF
authors.lastname: Manalo
authors.affiliation: Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California. Electronic address: jashinwu@hotmail.com.
authors.forename: Jashin J
authors.initials: JJ
authors.lastname: Wu
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D061214:Patient Safety; D011565:Psoriasis / Q000175:diagnosis* / Q000188:drug therapy*; D020551:Pulse Therapy, Drug; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068879:Adalimumab; D000068800:Etanercept